Literature DB >> 1725527

Long-term persistence of hepatitis C virus antibodies in a single source outbreak.

S Dittmann1, M Roggendorf, J Dürkop, M Wiese, B Lorbeer, F Deinhardt.   

Abstract

The occurrence of antibodies to hepatitis C virus (HCV) was investigated in 81 patients who developed hepatitis non-A, non-B (HNANB) after parenteral administration of contaminated immunoglobulin to prevent Rh sensitization. Sera from 74 of the 81 patients (89.9%) were anti-HCV positive at either 6-12 months or 9-10 years after administration of immunoglobulin. Sera were not available from any patients at either of the times: however, 52 of 56 sera (92.9%) were anti-HCV positive 6-12 months after use of immunoglobulin, and anti-HCV was present in 45 of 65 sera (69.2%) 9-10 years after immunoglobulin treatment. Of the latter, only two of 13 (15.4%) sera from patients who recovered from hepatitis were anti-HCV positive, whereas 43 of 52 patients (82.7%) with chronic disease were anti-HCV positive. The ELISA using a recombinant antigen was found a good detector as marker for a HCV infection because 90% of patients infected by a common source became anti-HCV positive. However, 10 years after infection most patients who did not develop chronic disease no longer had detectable antibodies.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1725527     DOI: 10.1016/0168-8278(91)90076-n

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  19 in total

Review 1.  Adaptive immunity to the hepatitis C virus.

Authors:  Christopher M Walker
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

2.  Hepatitis C Virus Infection in Haemodialysis Patients: "Wolf in Sheep's Clothing".

Authors:  G S Chopra; R M Gupta; S R Gedela; P P Varma; R Rai; S K Nema
Journal:  Med J Armed Forces India       Date:  2011-05-30

3.  Survival of a national cohort of hepatitis C virus infected patients, 16 years after exposure.

Authors:  H E Harris; M E Ramsay; N J Andrews
Journal:  Epidemiol Infect       Date:  2005-10-28       Impact factor: 2.451

Review 4.  Liver disease.

Authors:  S D Ryder; R Williams
Journal:  Postgrad Med J       Date:  1994-03       Impact factor: 2.401

5.  The issue of anti-D: an integrated seamless approach from recognition of need to bedside administration.

Authors:  M J Ryan; S Joyce; N O'Brien; E Lynch; G Burke; M R Cahill
Journal:  Ir J Med Sci       Date:  2005 Jul-Sep       Impact factor: 1.568

6.  Prenatal RhD Testing: A Review of Studies Published from 2006 to 2008.

Authors:  Tobias Jörg Legler; Sina Patricia Müller; Alexander Haverkamp; Simon Grill; Sinuhe Hahn
Journal:  Transfus Med Hemother       Date:  2009-05-14       Impact factor: 3.747

7.  Hepatitis C virus targets DC-SIGN and L-SIGN to escape lysosomal degradation.

Authors:  Irene S Ludwig; Annemarie N Lekkerkerker; Erik Depla; Fons Bosman; René J P Musters; Stany Depraetere; Yvette van Kooyk; Teunis B H Geijtenbeek
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

8.  Immunosuppressive therapy and hepatitis C virus infection: the clinical course of liver disease.

Authors:  W H Grotz; T H Peters; H J Schlayer; G Kirste; H Berthold; H Felten; P J Schollmeyer; J W Rasenack
Journal:  J Mol Med (Berl)       Date:  1996-07       Impact factor: 4.599

9.  Sequence variability in the env-coding region of hepatitis C virus isolated from patients infected during a single source outbreak.

Authors:  M Höhne; E Schreier; M Roggendorf
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

Review 10.  Hepatitis C: progress and problems.

Authors:  J A Cuthbert
Journal:  Clin Microbiol Rev       Date:  1994-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.